NCT01568008

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 933 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting. Patients will be seen at baseline and at a follow-up visit approximately 8-12 weeks after baseline, as per normal clinical practice.

Conditions

• Open-Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Bimatoprost 0.01% ophthalmic solution	Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.

Timeline

• Start date: 2011-10-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2012-04-02
• Last updated: 2013-09-20
• Results posted: 2013-09-20

Locations

1 site across 1 country: Belgium